CARLSBAD, Calif., May 19, 2022 (GLOBE NEWSWIRE) — CB Therapeutics (the “Company”), a biotechnology and precision fermentation company focused on using cellular agriculture to produce environmentally-friendly products for human health, has been granted a new patent covering the use of microorganisms to produce tryptamines and their analogs, such as psilocybin and various other molecules found in…

Source

Previous articleDanish Synthetic Biology Drug Developer Octarine and British Clinical Research Organisation Clerkenwell Health Partner to Bring Innovative Psychedelics to Patients
Next articleWake Network, Inc. Receives Certificate of Drug Registration for Microdose Formulation in Jamaica